IDROCORTISONE ACETATO DYNACREN - 1 % CREMA 1 TUBO DA 30 G ( DrugBank: - )

1 disease
IDDisease name (Link within this page)Number of trials
272Fibrodysplasia ossificans progressiva1

272. Fibrodysplasia ossificans progressiva

Clinical trials : 39 /  Drugs : 38 - (DrugBank : 7) / Drug target genes : 27 - Drug target pathways : 95
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2021-002244-70-IT
(EUCTR)		23/11/2021A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged >=14 Years with Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies.Rollover Study; Multicentre, Phase III, Open-label Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged >=14 Years with Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed Study PVO-1A-301 or PVO-1A-202/PVO-1A-204 and May Benefit from Palovarotene Therapy. - PIVOINE Fibrodysplasia Ossificans Progressiva (FOP)
MedDRA version: 20.0;Level: PT;Classification code 10068715;Term: Fibrodysplasia ossificans progressiva;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]		Product Name: Palovarotene
Product Code: [IPN60120]
INN or Proposed INN: Palovarotene
Trade Name: IDROCORTISONE ACETATO DYNACREN - 1 % CREMA 1 TUBO DA 30 G
Product Name: IDROCORTISONE ACETATO DYNACREN 1% CREMA
Product Code: [-]
INN or Proposed INN: ACIDO FUSIDICO/IDROCORTISONE ACETATO		IPSEN PHARMA SASNULLNAFemale: yes
Male: yes		87Phase 3United States;France;Canada;Argentina;Spain;Brazil;Australia;United Kingdom;Italy;Sweden